The Claim

BPC 157 (a stable peptide) has demonstrated pro-angiogenic activity through activation of VEGF, CD34, and FVIII pathways in muscle and tendon injury models, and this pro-angiogenic signaling mechanism represents a plausible tumor-promoting hazard that has not been adequately investigated for oncological safety in humans.

Source: Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on “Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals 2025, 18, 185”

What the research says

Not yet evaluated

We are still looking at what the research says.

Supports

0score

Challenges

0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works

0 studies reviewed

In plain English

A peptide called BPC 157 helps grow new blood vessels in injured muscles and tendons, but scientists worry this same blood vessel growth could also help tumors grow - and they haven't done enough safety studies to check if it causes cancer.

See the scientific wording

BPC 157 has demonstrated pro-angiogenic activity through VEGF, CD34, and FVIII activation in muscle and tendon models, and this pro-angiogenic signaling represents a plausible tumor-promoting hazard that has not been adequately investigated for oncological safety.

Score breakdown, mechanism chain, raw evidence, ideal studies needed

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.